Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Vnda - The Real Truth

Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Monday released topline results from its randomized controlled clinical study (VP-VLY-686-2601) evaluating tradipitant to prevent nausea and vomiting induced by Novo Nordisk A/S (NYSE:NVO) Wegovy.

Benzinga · Nov 20, 2025

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

Benzinga · Nov 18, 2025

3 Biotech Stocks to Watch for Lucrative Gains

The biotech sector’s robust long-term growth is driven by strong government support, the rising foothold of personalized medicine, the growing number of orphan drug formulations, and rapid AI adoption. Hence, biotech stocks G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), and Royalty Pharma (RPRX) could be ideal additions to your watchlist. Keep…

StockNews.com · Apr 16, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Jumpstart Your Portfolio With These 3 Biotech Stocks

The biotech industry’s robust growth potential is fueled by scientific advancements, rapid technological adoption, and supportive government initiatives. Thus, you could consider investing in top biotech stocks Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Vanda Pharmaceuticals (VNDA) to strengthen your portfolio. Keep reading….

StockNews.com · Feb 26, 2024

3 Biotech Stocks to Buy for Investor Security

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, and technological breakthroughs. Therefore, fundamentally strong biotech stocks ANI Pharmaceuticals (ANIP), Vanda Pharmaceuticals (VNDA) and Corcept Therapeutics (CORT) might be ideal additions to your portfolio. Read on.

StockNews.com · Feb 1, 2024

Bionano Genomics (BNGO) Challengers: 3 Biotech Innovators to Buy Instead

With the rising aging population and the emergence of new diseases, the biotech industry appears poised for steady growth. Therefore, three quality biotech stocks, Vanda Pharmaceuticals (VNDA), Organogenesis Holdings (ORGO), and Exelixis (EXEL), could be better catches than Bionano Genomics (BNGO). Read on….

StockNews.com · Sep 22, 2023

4 Best Biotech Stocks According to POWR Ratings

Rapid advancements and soaring demand make the biotech sector well-positioned to witness significant growth in the foreseeable future. Given this backdrop, quality biotech stocks Amgen Inc. (AMGN), Regeneron Pharmaceuticals (REGN), United Therapeutics (UTHR), and Vanda Pharmaceuticals (VNDA) with “Strong Buy” ratings could be wise portfolio additions now. Read on….

StockNews.com · May 23, 2023

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks to Buy Now

The biotech industry is well-positioned to grow, given the inelastic demand, rapid advancements, and government initiatives. So, quality biotech stocks Biogen (BIIB), Alkermes (ALKS), and Vanda (VNDA) could be worth owning. Read on.

StockNews.com · May 11, 2023

3 Optimal Stocks to Own in April... At a Value

Although inflation has shown signs of easing, it remains elevated. Therefore, the possibility of further rate hikes remains. As fears of a recession rise, investors may consider buying fundamentally strong stocks NetScout Systems (NTCT), Central Puerto (CEPU), and Vanda Pharmaceuticals (VNDA), trading at discounts to their peers. Keep reading….

StockNews.com · Apr 13, 2023

Earnings Outlook For Vanda Pharmaceuticals

Vanda Pharmaceuticals (NASDAQ:VNDA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Vanda Pharmaceuticals will report an earnings per share (EPS) of $-0.01.

Benzinga · May 4, 2022

Vanda Pharmaceuticals: Q4 Earnings Insights

Vanda Pharmaceuticals (NASDAQ:VNDA) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · Feb 23, 2022

Why Are Vanda Pharma Shares Plunging Today?

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) shares are plunging after the company announced Phase 3 trial data of tradipitant in treating the symptoms of gastroparesis.

Benzinga · Feb 4, 2022

Coverage From

People

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

US Food and Drug Administration

Vertex Pharmaceuticals Incorporated

Regeneron Pharmaceuticals Inc

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.